Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control Rates
In This Article:
Immuneering (IMRX) said Tuesday that new data from an ongoing phase 2a trial of its lead candidate I
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.